The discovery was selected by the European Respiratory Society (ERS) as a “Late Breaking Abstract” in thecategory ‘Best abstracts in COVID-19’ and today, Investigation leader, Suzana Tanni presented the results of the recently concluded open-labeled, randomized clinical trial (BREATH), which show that ten days of Breathox® use halved the time for resolution of COVID-19-induced cough in patients with confirmed and symptomatic COVID-19 within 10 days of symptom onset.
The data add to a growing body of in-vitro, clinical, and real-world data elucidating the benefits of the treatment form invented by LIITA Care; inhaled micronized dry NaCl.
“First of all, we are pleased to see that our in-vitro findings also seem to translate into an anti-viral effect in a clinical setting. The data points toward BREATHOX® as safe and effective in reducing the impact of Covid-19. We see the European Respiratory Society’s selection of our results as an endorsement of our research and the vast treatment potential that the result implies” says LIITA Care CEO Martin Ohrt.
“We are currently planning larger trials needed to further elucidate the risks and benefits of our treatment form, and we hope that the publication of our discoveries will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”